WO1994006453A1 - Antagonistes de la bradykinine contenant des acides amines aliphatiques en position 5 - Google Patents
Antagonistes de la bradykinine contenant des acides amines aliphatiques en position 5 Download PDFInfo
- Publication number
- WO1994006453A1 WO1994006453A1 PCT/US1993/008220 US9308220W WO9406453A1 WO 1994006453 A1 WO1994006453 A1 WO 1994006453A1 US 9308220 W US9308220 W US 9308220W WO 9406453 A1 WO9406453 A1 WO 9406453A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- arg
- bradykinin
- aliphatic
- pro
- cpg
- Prior art date
Links
- 239000003152 bradykinin antagonist Substances 0.000 title claims abstract description 34
- -1 aliphatic amino acids Chemical class 0.000 title description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 46
- UYRCOTSOPWOSJK-JXTBTVDRSA-N bradykinin antagonist Chemical compound C1C2=CC=CC=C2CC1[C@@H](NC(=O)C(CO)NC(=O)C(NC(=O)CNC(=O)[C@H]1N(C[C@H](O)C1)C(=O)C1N(CCC1)C(=O)C(CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=N)CCCCCCC(=N)N[C@H](CCCNC(N)=N)C(=O)NC(CCCNC(N)=N)C(=O)N1C(CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)NC(C1CC2=CC=CC=C2C1)C(=O)NC(CO)C(=O)N[C@H](C1CC2=CC=CC=C2C1)C(=O)N1C2CCCCC2CC1C(=O)NC(CCCNC(N)=N)C(O)=O)C1CC2=CC=CC=C2C1)C(=O)N1C2CCCCC2CC1C(=O)NC(CCCNC(=N)N)C(O)=O UYRCOTSOPWOSJK-JXTBTVDRSA-N 0.000 claims abstract description 22
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 21
- 125000002723 alicyclic group Chemical group 0.000 claims abstract description 9
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 37
- 101800004538 Bradykinin Proteins 0.000 claims description 34
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 102100035792 Kininogen-1 Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 26
- 102400000967 Bradykinin Human genes 0.000 description 32
- 239000005557 antagonist Substances 0.000 description 27
- 238000005859 coupling reaction Methods 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 230000036515 potency Effects 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229910004373 HOAc Inorganic materials 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- FYSKZKQBTVLYEQ-FSLKYBNLSA-N Kallidin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 FYSKZKQBTVLYEQ-FSLKYBNLSA-N 0.000 description 3
- 108010003195 Kallidin Proteins 0.000 description 3
- 108010093008 Kinins Proteins 0.000 description 3
- 102000002397 Kinins Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 241000256856 Vespidae Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 108010004034 stable plasma protein solution Proteins 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- CLPZNYCYBYIODB-RZKHNPSRSA-N (1s)-2-azabicyclo[3.1.0]hexane-1-carboxylic acid Chemical compound C1CN[C@]2(C(=O)O)C1C2 CLPZNYCYBYIODB-RZKHNPSRSA-N 0.000 description 1
- DMBKPDOAQVGTST-GFCCVEGCSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylmethoxypropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)COCC1=CC=CC=C1 DMBKPDOAQVGTST-GFCCVEGCSA-N 0.000 description 1
- SSXPFNXUSFJJEI-BHEJXMHWSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-4-methylsulfanylbutanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3- Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 SSXPFNXUSFJJEI-BHEJXMHWSA-N 0.000 description 1
- WBIIPXYJAMICNU-AWEZNQCLSA-N (2s)-5-[amino-[(4-methylphenyl)sulfonylamino]methylidene]azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC1=CC=C(S(=O)(=O)NC(N)=NCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C=C1 WBIIPXYJAMICNU-AWEZNQCLSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- JZUMPNUYDJBTNO-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 JZUMPNUYDJBTNO-UHFFFAOYSA-N 0.000 description 1
- XBPKRVHTESHFAA-UHFFFAOYSA-N 2-azaniumyl-2-cyclopentylacetate Chemical compound OC(=O)C(N)C1CCCC1 XBPKRVHTESHFAA-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 description 1
- 208000003014 Bites and Stings Diseases 0.000 description 1
- 102000010183 Bradykinin receptor Human genes 0.000 description 1
- 108050001736 Bradykinin receptor Proteins 0.000 description 1
- 101710097732 Bradykinin-related peptides Proteins 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 229930182832 D-phenylalanine Natural products 0.000 description 1
- 208000008279 Dumping Syndrome Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- 108700018740 Met-Lys- bradykinin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000032395 Post gastric surgery syndrome Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- WNNNWFKQCKFSDK-UHFFFAOYSA-N allylglycine Chemical compound OC(=O)C(N)CC=C WNNNWFKQCKFSDK-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 101150010139 inip gene Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000000956 myotropic effect Effects 0.000 description 1
- UBLQIESZTDNNAO-UHFFFAOYSA-N n,n-diethylethanamine;phosphoric acid Chemical compound [O-]P([O-])([O-])=O.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC UBLQIESZTDNNAO-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- CQYBNXGHMBNGCG-RNJXMRFFSA-N octahydroindole-2-carboxylic acid Chemical compound C1CCC[C@H]2N[C@H](C(=O)O)C[C@@H]21 CQYBNXGHMBNGCG-RNJXMRFFSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 102220043690 rs1049562 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 102000027509 sensory receptors Human genes 0.000 description 1
- 108091008691 sensory receptors Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/18—Kallidins; Bradykinins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to novel biologically active peptides which act as antagonists of the biological activities of bradykinin and its homologs and congeners, their pharmaceutically acceptable salts, and their application as therapeutic agents. More particularly, the invention pertains to modified bradykinin antagonist peptides that do not contain any aromatic amino acids or at least no aromatic residue in the 5-position and preferably also none in the 7- and 8-positions. Heretofore, all bradykinin antagonist peptides have had an aromatic or substituted aromatic amino acid residue at the position analogous to that of position 5 of bradykinin.
- the bradykinin antagonist peptides of the present invention contain aliphatic, alicyclic, aliphatic heterocyclic or substituted alicyclic or aliphatic heterocyclic amino acid residues at that position.
- Bradykinin (usually abbreviated BK) has the amino acid sequence:
- bradykinin Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (BK) position : 1 2 3 4 5 6 7 8 9
- Lys-BK also called kallidin
- Met-Lys-BK Met-Lys-BK.
- humans also produce the analog in which the 3-proline is replaced by trans- 4-hydroxyproline.
- Bradykinin and its physiologically important related peptides kallidin (Lys-bradykinin) and Met-Lys-bradykinin, exhibit physiological actions which qualify them as mediators of inflammatory reactions, hypotensive states, and pain. Bradykinin is overproduced in pathological conditions such as septic shock (Robinson et al. , Am. J. Med.. 5_9.:61, 1975) and hemorrhagic (Hirsch et al . , J. Surg. Res. , 37:147, 1974), anaphylaxis
- bradykinin The production of bradykinin from the plasma results in pain at the site of the pathological condition, and the overproduction intensifies the pain directly or via stimulation by bradykinin of the activation of the arachidonic acid pathway which produces prostaglandins and leukotrienes, the more distal and actual mediators of inflammation.
- Literature references describing these actions of bradykinin and related peptides are found in Handbook of Experimental Pharmacology, Vol. 25, Springer-Verlag, 1970 and VOl . 25 Supplement, 1979 and in Stewart, in "Mediators of the Inflammatory Process", Henson and Murphy, eds. , Elsevier, 1989.
- Bradykinin as discussed, has been found to be produced in inflammatory reactions in the intestine provoking contraction of smooth muscle and secretion of fluid and ions.
- the existence of specific bradykinin receptors in the mucosal lining of the intestine and intestinal smooth muscle is demonstrated by Manning et al . in Nature (229 :256- 259, 1982) showing the influence of bradykinin in very low concentrations upon fluid and ion secretion.
- bradykinin and associated pain in angina has been studied and reported by Kimura et al . in American Heart Journal ( 5.:635-647, 1973) and by Staszewska-Barczak et al. in Cardiovascular Research ( ⁇ j) :314-327, 1976) .
- the reported action of bradykinin and prostaglandins acting in concert are the natural stimulus for excitation of the sensory receptors signalling the pain of myocardial ischaemia.
- Bradykinin and bradykinin-related kinins are not only produced by the animal but may also be injected as a result of stings and bites. It is known that insects such as hornets and wasps inject bradykinin related peptides which also cause pain, swelling and inflammation.
- bradykinin which is essential for the development of useful tools for diagnostic use, and for the development of therapeutic agents aimed at alleviating the intense pain and other symptoms caused by the production and overproduction of bradykinin, was severely hindered by the lack of specific sequence-related competitive antagonists of bradykinin until the discovery of the first effective bradykinin antagonists by Vavrek and Stewart in 1985. (Peptides. £.161-164, 1985; U.S. Patent 4,693,993, September 15, 1987) .
- bradykinin In all those peptide antagonists of bradykinin, the proline residue at position 7 of bradykinin was replaced by a D-aromatic acid residue, usually D-phenylalanine or D-thienylalanine.
- a D-aromatic acid residue usually D-phenylalanine or D-thienylalanine.
- many modifications of the original bradykinin antagonists have been described, but all effective antagonists have had an aromatic amino acid residue at position 5 and a D-aromatic residue at position 7.
- the residue at position 8 was usually an aromatic amino acid, although in certain antagonists, the 5-7-8 arrangement was aromatic-D-aromatic-aliphatic. More recently, effective bradykinin antagonists have been described in which the 5-7-8 arrangement is aromatic-D-aliphatic-aliphatic (R.J. Vavrek and J.M. Stewart in "Kinins 1991", H. Fritz, ed. , Agents and Actions Supplement, 1992; D.J. Kyle et al., J. Med. Chem.. 34_:2649-2653, 1991) .
- the prior art has not described effective bradykinin antagonists having the 5-7-8 arrangement of aliphatic-D-aliphatic-aliphatic or aliphatic, D- aromatic, aliphatic. Effective, potent bradykinin antagonists having this type of structure are the subject of this invention.
- the structures of effective bradykinin antagonist peptides described in the prior art can be summarized as follows:
- bradykinin antagonists are also known in which other residues are used, such as:
- This invention relates to modification of the structures of known bradykinin antagonist peptides to replace the aromatic amino acid residue at position 5 of the bradykinin antagonist structure with an aliphatic, alicyclic, or substituted alicyclic amino acid residue.
- bradykinin analogs were previously synthesized as potential antagonists having an aliphatic amino acid residue at position 5, but always in combination with a position 7-8 substitution that was
- bradykinin antagonist peptides of the present invention may be characterized by Formula 3 :
- Formula 3 X--A--B--C--D--E--F--G--H--J--K--Z position number 0 1 2 3 4 5 6 7 8 9
- X is an aromatic, aliphatic, or urethane-type acylating group, a single amino acid of the D- or L- configuration, or a di- or poly-peptide containing amino acids of the D- or L- configuration, or a combination of these
- A is D-Arg or another basic or neutral aromatic, aliphatic, heterocyclic or alicyclic amino acid of the D- or L- configuration
- B is Arg or another basic or neutral aromatic, aliphatic, heterocyclic or alicyclic amino acid of the D- or L- configuration
- C is Pro, Hyp, or another basic or neutral aromatic, aliphatic, heterocyclic, or alicyclic amino acid of the D- or L- configuration
- D is Pro, Hyp, or another basic or neutral aromatic, aliphatic, heterocyclic, or alicyclic amino acid of the D- or L- configuration
- E is Gly or another basic or neutral aromatic, aliphatic, heterocyclic, or alicyclic amino acid of the D- or L- configuration
- F is Cpg or another aliphatic, aliphatic heterocyclic, or alicyclic amino acid of the D- or L- configuration
- G is preferably Ser or Cys of the D- or L- configuration or another aromatic, aliphatic, heterocyclic, or alicyclic amino acid of the D- or L- configuration
- H is D-Cpg or another aliphatic, aliphatic heterocyclic, or alicyclic amino acid of the
- J is Cpg or another aliphatic, aliphatic heterocyclic, or alicyclic amino acid of the D- or L- configuration
- K is Arg or another basic or neutral aromatic, aliphatic, heterocyclic or alicyclic amino acid of the D- or L- configuration
- Z is the carboxy-terminal carboxyl group or a carboxy-terminal extension composed of an amino acid of the D- or L-configuration or a peptide composed of amino acids of the D- or L-configuration.
- Salts of bradykinin antagonist peptides of Formula 3 include salts with HCl, TFA, HOAc, as well as other pharmaceutically acceptable salts. Suitable substitutions in the various positions of all-aliphatic bradykinin antagonists peptides of Formula 3 may be represented as follows (alignment of the residues in a particular row does not imply nor limit to a given peptide sequence) :
- bradykinin antagonist peptides of the present invention may be more exactly represented by Formula 4 :
- a preferred compound of Formula 4 is the following peptide:
- bradykinin antagonist peptides of the present invention by SPPS may be carried out manually (see Stewart & Young) or by use of the Beckman Model 990, Biosearch Model 9500 or other automatic peptide synthesizers, and involves use of standard procedures, defined as follows:
- PROCEDURE A DCC coupling reaction:
- PROCEDURE B DIC coupling:
- PROCEDURE D TFA deprotection and neutralization: (Stewart & Young p. 76) .
- the deprotection reagent is TFA:DCM (1:3) , containing 1 mg/ml indole. It is used for 30 minutes, following a prewash.
- the neutralization reagent is 10% TEA in DCM, prepared fresh and used twice for one minute.
- PROCEDURE F HF cleavage and deblocking: (Stewart & Young p. 85) .
- PROCEDURE G PURIFICATION OF PEPTIDES:
- the peptides may be purified by CCD for 100 transfers in the appropriate system, as determined by preliminary k estimation:
- Chlorine-tolidine and Sakaguchi spray reagents may be used.
- PROCEDURE J Paper electrophoresis (ELEC) :
- ELEC may be done in buffers of pH 2.8 and 5.0 as described in Stewart & Young. Chlorine-tolidine and Sakaguchi spray reagents may be used.
- Preparative HPLC may be carried out on large-pore reversed phase C4 or C8 columns in a gradient of 0.1% TFA in H20 to 0.08% TFA in acetonitrile. Detection may be by UV at 214 nm. Analytical HPLC may be carried out in the same system and in a gradient of acetonitrile in 0.25M triethylammonium phosphate, pH 6.5.
- PROCEDURE L MASS spectroscopy
- Peptides may be checked for- the correct molecular mass by FAB mass spectroscopy.
- PROCEDURE M Amino acid analysis (AAA) :
- Peptides may be hydrolyzed in 6N HCl and analyzed as described in Stewart &. Young, pp. 109-
- the 990 synthesizer vessel is loaded with 1.66g of Boc-Arg(Tos) -OHMR (0.24 mmol/g substitution; 0.4 mmol total) .
- Boc-L-Cpg is coupled by Procedure C. Coupling is checked for completeness with the Kaiser test, and is repeated if necessary.
- Boc-D-Cpg and Boc-Ser(Bzl) are next coupled in order using Procedure C.
- the peptide-resin is divided into 4 parts, and synthesis was continued on the 0.1 mmol scale, using BOP procedure C. The peptide-resin is deprotected by Procedure E and dried.
- the peptide is cleaved from the resin and deblocked by Procedure F.
- the peptide is purified by CCD using Procedure G and System A.
- the purified peptide is checked for purity by TLC (Procedure H) , ELEC (Procedure I) and HPLC (Procedure K) , and characterized by AAA (Procedure M) and MASS (Procedure L) .
- TLC Process H
- ELEC Protectedure I
- HPLC Procedure K
- AAA Procedure M
- MASS Procedure L
- bradykinin antagonists are assayed on isolated rat uterus in natural or induced estrus and on guinea pig ileum, according to the commonly accepted assay methods for bradykinin and related kinins as described by Trautschold (Handbook of Expt. Pharmacol., Vol. 25, Springer Verlag, pp. 53- 55, 1969) for inhibition of the myotropic activity of bradykinin.
- the inhibition potencies are determined according to the commonly accepted manner described by Schild for antagonists of biologically active compounds (Br. J. Pharmacol.. 2..189, 1947), and expressed as pA values. In the assays, a dose- response curve is determined for the reference substance bradykinin.
- the dose of bradykinin which produces a half-maximal contraction of tissue is the ED dose.
- An amount of bradykinin equivalent to twice the ED dose is administered to the tissue 30 seconds after the start of incubation of the tissue with a dose of antagonist.
- Doses of antagonist are increased in the protocol until the dose of antagonist is found that causes the tissue response to a double ED 50 dose of bradykinin in the presence of antagonist to equal the response of an EDb_ n (J dose of bradykinin without antagonist.
- the pA value represents the negative logarithm of the molar concentration of antagonist necessary to reduce the response of a double ED dose of bradykinin to that of an ED dose without antagonist.
- a change of one unit of pA value represents an order of magnitude change in potency.
- the negative log of the dose of BK that half-maximal contraction of the tissues, is commonly known as the pD value.
- the pD value for bradykinin is 7.9 on the rat uterus and 7.4 on the guinea pig ileum.
- bradykinin antagonists The m vivo effects of bradykinin antagonists on blood pressure in the anesthetized rat are determined according to the assay described by Roblero, Ryan and Stewart (Res. Commun. Pathol. Pharmacol. , 6.:207, 1973) .
- the antagonists produce inhibition of the bradykinin response when injected as a bolus admixture of bradykinin plus antagonist by either the ia or iv route of administration, or when administered as an infusion. Potencies for the antagonist in this assay are not reported quantitatively but rather are indicated qualitatively. The results of tests on compounds of the various Examples are reported in Table I.
- Antagonist potency is given as percent of BK potency.
- Antagonist potency is given as pA foi and is underlined.
- blood pressure assay ⁇ indicates unquantitated antagonist potency.
- the antagonists of the invention may be used in the form of conventional pharmaceutical compositions comprising the antagonist and a pharmaceutically acceptable carrier. Such compositions may be adapted for topical, oral, aerosolized, intramuscular, subcutaneous or intravenous administration.
- the amount of antagonist present in such compositions will range from, for example, about 0.001 to 90.0% by weight depending on the application and mode of administration although more or less of the active component may be used.
- Conventional dosages will vary considerably on the basis of the intended application and mode of administration, e.g. 0.1 to 100 micrograms per kg body weight per minute are contemplated for use in the context of the septic shock.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention se rapporte à des peptides antagonistes de la bradykinine qui ont un résidu hétérocyclique aliphatique, alicyclique ou aliphatique en position 5 et de préférence en positions 7 et 8.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU50985/93A AU5098593A (en) | 1992-09-11 | 1993-09-08 | Bradykinin antagonists containing aliphatic amino acids in the 5-position |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94231792A | 1992-09-11 | 1992-09-11 | |
US07/942,317 | 1992-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994006453A1 true WO1994006453A1 (fr) | 1994-03-31 |
Family
ID=25477912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/008220 WO1994006453A1 (fr) | 1992-09-11 | 1993-09-08 | Antagonistes de la bradykinine contenant des acides amines aliphatiques en position 5 |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5098593A (fr) |
WO (1) | WO1994006453A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2739553A1 (fr) * | 1995-10-06 | 1997-04-11 | Oreal | Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute |
EP0836853A1 (fr) * | 1996-10-14 | 1998-04-22 | Hoechst Aktiengesellschaft | Utilisation des antagonistes de bradykinin pour la fabrication d'un médicament pour le traitement de la maladie d'Alzheimer |
US5834431A (en) * | 1995-09-08 | 1998-11-10 | Cortech, Inc. | Des-Arg9 -BK antagonists |
US5863901A (en) * | 1996-03-27 | 1999-01-26 | Hoechst Aktiengesellschaft | Use of bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders and acute liver disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4693993A (en) * | 1985-06-13 | 1987-09-15 | Stewart John M | Bradykinin antagonist peptides |
-
1993
- 1993-09-08 WO PCT/US1993/008220 patent/WO1994006453A1/fr active Application Filing
- 1993-09-08 AU AU50985/93A patent/AU5098593A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4693993A (en) * | 1985-06-13 | 1987-09-15 | Stewart John M | Bradykinin antagonist peptides |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834431A (en) * | 1995-09-08 | 1998-11-10 | Cortech, Inc. | Des-Arg9 -BK antagonists |
FR2739553A1 (fr) * | 1995-10-06 | 1997-04-11 | Oreal | Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute |
WO1997013493A1 (fr) * | 1995-10-06 | 1997-04-17 | L'oreal | Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute |
US6468972B1 (en) | 1995-10-06 | 2002-10-22 | Societe L'oreal S.A. | Method to promote, stimulate and/or delay hair loss by a brady kinin antagonist |
US5863901A (en) * | 1996-03-27 | 1999-01-26 | Hoechst Aktiengesellschaft | Use of bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders and acute liver disorders |
EP0836853A1 (fr) * | 1996-10-14 | 1998-04-22 | Hoechst Aktiengesellschaft | Utilisation des antagonistes de bradykinin pour la fabrication d'un médicament pour le traitement de la maladie d'Alzheimer |
US6245736B1 (en) | 1996-10-14 | 2001-06-12 | Aventis Pharma Deutschland Gmbh | Use of peptidic bradykinin antagonists for the treatment and prevention of Alzheimer's disease |
Also Published As
Publication number | Publication date |
---|---|
AU5098593A (en) | 1994-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4693993A (en) | Bradykinin antagonist peptides | |
US4923963A (en) | Bradykinin antagonist peptides | |
US4801613A (en) | Bradykinin antagonist peptides | |
EP0315367B1 (fr) | Polypeptides | |
HU206376B (en) | Process for producing lh-rh antagonists and pharmaceutical compositions comprising same | |
US5834431A (en) | Des-Arg9 -BK antagonists | |
CA2049743A1 (fr) | Antagonistes de la bradykinine | |
JP3465000B2 (ja) | ブラジキニン型ペプチド | |
JPS61191698A (ja) | 新規な環状ヘキサペプチドlhrh拮抗剤 | |
US4604378A (en) | Basic V1 -vasopressin antagonists | |
EP0328090A2 (fr) | Analogues du LHRH | |
US4684622A (en) | Compositions and methods for producing vasodilation and antioxytocic activity | |
US4599324A (en) | V1-vasopressin antagonists | |
US6458923B1 (en) | Modified position (7) bradykinin antagonist peptides | |
WO1994006453A1 (fr) | Antagonistes de la bradykinine contenant des acides amines aliphatiques en position 5 | |
US4876243A (en) | Vasopressin compounds | |
US5648336A (en) | Bradykinin antagonist peptides containing indane-substituted amino acids | |
WO1989001780A1 (fr) | Peptides antagonistes de bradykinine | |
US5543496A (en) | Cyclic bradykinin antagonist peptides | |
US4684621A (en) | Methods of producing vasodilation or antioxytocic activity | |
EP0234935A2 (fr) | Composés vasopressine | |
US4826813A (en) | 4'-Methyl-β-mercapto-β,β-cyclopentamethylenepropionic acid vasopressin antagonists | |
US4658015A (en) | Polypeptide intermediates | |
US5502164A (en) | Peptide compounds having therapeutic activity | |
US6770741B1 (en) | Bradykinin antagonist peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
NENP | Non-entry into the national phase |
Ref country code: CA |